A phase 2 multi-center, randomized, open-label study of two dose levels of IMOxine (IMO-2055 for injection) in patients with metastatic or locally recurrent clear cell renal carcinoma
Phase of Trial: Phase II
Latest Information Update: 15 Jun 2018
At a glance
- Drugs IMO 2055 (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 26 Sep 2009 Final data was presented during the Eighth International Kidney Cancer Symposium 2009, according to Idera Pharmaceuticals.
- 08 Jan 2009 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 15 Oct 2008 Primary endpoint was not met according to Idera Pharmaceuticals media release.